Abstract
Effective treatment of resistant hypertension still remains an unmet goal of antihypertensive drug treatment. The DORADO trial recently evaluated the efficacy and safety profile of the selective endothelin receptor blocker darusentan in almost 400 hypertensive patients treated with more than four antihypertensive drugs (including a diuretic) but without effective blood pressure control. The trial results show that > 50% of patients treated with the drug exhibit clinical blood pressure < 140/90 mmHg and well-controlled ambulatory blood pressure values. Darusentan, however, was associated with a high incidence of peripheral edema and fluid retention, a side effect that may reduce the safety profile of the drug and its tolerability. Although these data are promising, the drug requires further evaluation, with particularly regard to the long term.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
